The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial.
Stephanie Clisant
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer
Bernadette Lieg-Atzwanger
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Ferdinand Ploner
No relevant relationships to disclose
Sophie Taieb
No relevant relationships to disclose
Marie Vanseymortier
No relevant relationships to disclose
Axel Le Cesne
No relevant relationships to disclose
Wolfgang Eisterer
No relevant relationships to disclose
Olivier Mir
No relevant relationships to disclose
Antoine Italiano
No relevant relationships to disclose
Pierre Arvis
Employment or Leadership Position - Bayer
Andrew Kramar
No relevant relationships to disclose
Jean-Yves Blay
No relevant relationships to disclose
Thomas Brodowicz
Research Funding - Bayer